Omeros Corporation (NASDAQ:OMER)’s share price was down 4.8% during mid-day trading on Tuesday . The stock traded as low as $10.90 and last traded at $10.95, with a volume of 219,060 shares trading hands. The stock had previously closed at $11.50.

Several research firms recently weighed in on OMER. FBR & Co restated an “outperform” rating and set a $38.00 price target on shares of Omeros Corporation in a research report on Wednesday, June 29th. Zacks Investment Research lowered Omeros Corporation from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. Wedbush restated an “outperform” rating and set a $62.00 price target on shares of Omeros Corporation in a research report on Tuesday, May 10th. Cantor Fitzgerald began coverage on Omeros Corporation in a research report on Thursday, June 2nd. They set a “buy” rating and a $21.00 price target on the stock. Finally, WBB Securities restated a “buy” rating and set a $75.00 price target on shares of Omeros Corporation in a research report on Tuesday, June 14th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $38.22.

The company has a 50 day moving average of $11.09 and a 200-day moving average of $12.15. The company’s market cap is $422.66 million.

Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.11. The firm earned $7.40 million during the quarter, compared to analysts’ expectations of $8.79 million. During the same quarter last year, the firm posted ($0.51) EPS. The business’s revenue for the quarter was up 1797.4% on a year-over-year basis. On average, analysts anticipate that Omeros Corporation will post ($1.76) EPS for the current fiscal year.

In other news, VP Marcia S. Kelbon sold 15,900 shares of the stock in a transaction that occurred on Wednesday, June 15th. The stock was sold at an average price of $11.42, for a total value of $181,578.00. Following the sale, the vice president now directly owns 179,497 shares in the company, valued at $2,049,855.74. The sale was disclosed in a document filed with the SEC, which is available at this link.

Other large investors have modified their holdings of the company. Nationwide Fund Advisors increased its stake in shares of Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock valued at $1,096,000 after buying an additional 45,145 shares during the last quarter. California State Teachers Retirement System increased its position in Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock valued at $1,103,000 after buying an additional 1,249 shares during the last quarter. Mutual of America Capital Management LLC increased its position in Omeros Corporation by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 116,171 shares of the biopharmaceutical company’s stock valued at $1,827,000 after buying an additional 694 shares during the last quarter. Brown Advisory Inc. increased its position in Omeros Corporation by 44.6% in the fourth quarter. Brown Advisory Inc. now owns 529,699 shares of the biopharmaceutical company’s stock valued at $8,332,000 after buying an additional 163,306 shares during the last quarter. Finally, Bank of Montreal Can increased its position in Omeros Corporation by 52.0% in the fourth quarter. Bank of Montreal Can now owns 1,327,706 shares of the biopharmaceutical company’s stock valued at $20,885,000 after buying an additional 454,055 shares during the last quarter.

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.